Circulating Tumor DNA and [<sup>18</sup>F]FDG-PET for Early Response Assessment in Patients with Advanced NSCLC

Circulating Tumor DNA and [<sup>18</sup>F]FDG-PET for Early Response Assessment in Patients with Advanced NSCLC

<b>Background/Objectives</b>: Identifying treatment failure at earlier time points to could spare cancer patients from ineffective treatment and side effects. In this study, circulating tumor DNA (ctDNA) and [<sup>18</sup>F]FDG-PET/CT were investigated during the first cycle...

Full description

Bibliographic Details
Main Authors: Heidi Ryssel, Lise Barlebo Ahlborn, Danijela Dejanovic, Sune Hoegild Keller, Mette Pøhl, Olga Østrup, Annika Loft, Barbara Malene Fischer, Seppo Wang Langer, Andreas Kjaer, Tine Nøhr Christensen
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Diagnostics
Subjects:
keyword 1
non-small cell lung cancer 2
circulating tumor DNA 3
[<sup>18</sup>F]FDG-PET/CT 4
early response evaluation 5
MTV 6
Online Access:https://www.mdpi.com/2075-4418/15/3/247

Internet

https://www.mdpi.com/2075-4418/15/3/247

Similar Items